Spirometry for Inhaled Insulin
Adults with type 1 and type 2 diabetes now have a new option for their control medications.
In June 2014, the FDA approved a rapid acting inhaled insulin (market name: Afrezza®) indicated to improve glycemic control in adult patients with diabetes mellitus. Because of the effect inhaled insulin has on pulmonary function, the FDA and the insulin manufacturer have determined that all patients must have spirometry (specifically FEV1) assessed prior to initiating therapy and regularly therafter.
BEFORE Initiating Inhaled Insulin Therapy:
AFTER Initiating Inhaled Insulin Therapy:
Because initial qualification and ongoing monitoring is required, we understand that you may have questions about spirometer selection, training and reimbursement.
Through a partnership with MIR Medical, MGC Diagnostics Corporation is able to offer a special 6 month offer on the Spirobank II® spirometer starter kit and supplies.
Starter Kit: $398.50*
*price includes ground shipping. Add an additional $31.75 for 2nd day shipping or $57.50 for overnight shipping.
The Spirobank II is a handheld multifunction spirometer with graphical display. It is the ideal device for family doctors, primary care and occupational medicine facilities, and general screening. The Spirobank II complies with the latest ATS/ERS standards for accuracy.
Fill Out Order Form Here
NOTE: This information is not a substitute for medical advice and does not provide a complete summary of any inhaled insulin product or address all considerations in making treatment decisions regarding their use. Always refer to the complete product information provided by the insulin manufacturer.